Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2016 09:45 ET | Source: Morphosys AG

MorphoSys Announces Presentations of Clinical Data at Upcoming American Society of Hematology (ASH) Annual Meeting 2016

Martinsried / Munich, Germany, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Oral presentations on proprietary antibody programs MOR208 and MOR202 MorphoSys AG (FSE: MOR; Prime Standard Segment;...
November 02, 2016 02:34 ET | Source: MorphoSys AG

MorphoSys and LEO Pharma Enter into Strategic Alliance to Develop Therapeutic Antibodies in Dermatology

MARTINSRIED / MUNICH, Germany, Nov. 2, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) and LEO Pharma today announced that they have entered into a...
October 28, 2016 05:33 ET | Source: MorphoSys AG

MorphoSys to Host Q3 2016 Conference Call on November 7, 2016

MARTINSRIED / MUNICH, Germany, Oct. 28, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) will publish its first nine months' 2016 results on November 7, 2016 at 7:00 am...
October 20, 2016 01:34 ET | Source: MorphoSys AG

MorphoSys Receives Clinical Milestone for Start of Phase 1 Trial with Novel Cancer Antibody

MARTINSRIED / MUNICH, Germany, Oct. 20, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that it has received a milestone payment from...
October 17, 2016 01:35 ET | Source: MorphoSys AG

MorphoSys Presents Updated Clinical Results for MOR202 at Medical Conference

MARTINSRIED / MUNICH, Germany, Oct. 17, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) presented updated safety and efficacy data from an ongoing phase...
October 01, 2016 06:51 ET | Source: MorphoSys AG

MorphoSys Announces That Its Licensee Janssen Reports Positive Results From A Phase 3 Study of Guselkumab in Plaque Psoriasis

Martinsried / Munich, Germany, Oct. 1, 2016 (GLOBE NEWSWIRE) -- Guselkumab Met Co-Primary Endpoints in Patients with Moderate to Severe Plaque Psoriasis Janssen today presented results from a...
October 01, 2016 06:48 ET | Source: MorphoSys AG

Ad hoc: MorphoSys Announces That Its Licensee Janssen Reports Positive Results From A Phase 3 Study of Guselkumab in Plaque Psoriasis

Martinsried / Munich, Germany, Oct. 1, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that its licensee Janssen Research &...
September 29, 2016 01:36 ET | Source: MorphoSys AG

MorphoSys and Galapagos Start First-In-Patient Dosing of IL-17C Antibody MOR106 in Atopic Dermatitis

Ongoing phase 1 study in healthy volunteers now advanced to investigate MOR106 in patients with atopic dermatitis Favorable safety results shown in healthy volunteers receiving single...
September 19, 2016 01:40 ET | Source: MorphoSys AG

Lanthio Pharma Expands Management Team

MARTINSRIED / MUNICH, Germany, Sept. 19, 2016 (GLOBE NEWSWIRE) -- The Dutch biopharmaceutical company Lanthio Pharma B.V., a wholly owned subsidiary of MorphoSys AG (FSE: MOR; Prime Standard Segment,...
September 12, 2016 01:38 ET | Source: MorphoSys AG

MorphoSys Appoints Four R&D Experts to its Newly Formed Scientific Advisory Board

MARTINSRIED / MUNICH, Germany, Sept. 12, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) today announced the appointment of four leading experts to its...